NFGH
SRPT icon

Nan Fung Group Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Nan Fung Group Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,917
Closed -$294K – 41
2022
Q2 		$294K Hold
3,917
– – 0.2% 32
2022
Q1 		$306K Buy
+3,917
New +$300K 0.15% 36

Other funds holding SRPT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nan Fung Group Holdings's SRPT Position: Q3 2022 in Review

Nan Fung Group Holdings sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 3,917 shares — an estimated $294K sold.

Nan Fung Group Holdings first reported a position in SRPT in Q1 2022 and held it in 2 quarters. The position peaked at $306K in Q1 2022. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

  • Nan Fung Group Holdings reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nan Fung Group Holdings sold 3,917 Sarepta Therapeutics shares in Q3 2022, an estimated $294K.
  • Nan Fung Group Holdings first reported a position in Sarepta Therapeutics in Q1 2022 and held it in 2 quarters.
  • Nan Fung Group Holdings's Sarepta Therapeutics position peaked at $306K in Q1 2022.
  • 375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Nan Fung Group Holdings's 13F filing for Q3 2022, filed 10 Nov 2022.